ASAbhisek Satapathy

Abhisek Satapathy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Abhisek Satapathy has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Nanotechnology-enhanced liquid biopsies and genomic biomarkers: Emerging landscapes for early cancer detection

    by Poonam Sahu, Abinash Satapathy, Abhisek Satapathy, Trilochan Satapathy


  • Nano-engineered phytochemicals in cancer therapy: mechanistic insights into apoptosis, ferroptosis, tumor microenvironment modulation and drug resistance reversal

    by Poonam Sahu, Trilochan Satapathy, Abhisek Satapathy, Abinash Satapathy

    Cancer progression and therapeutic resistance are driven by interconnected mechanisms involving redox imbalance, metabolic plasticity, epigenetic remodeling and tumor microenvironment (TME)-mediated immune suppression. Conventional “one drug-one target” therapies often fail to overcome these adaptive oncogenic networks, resulting in multidrug resistance and disease relapse. This review aims to explore the therapeutic potential of nano-engineered phytochemicals in cancer management, with emphasis on ferroptosis induction, oncogenic pathway modulation and TME reprogramming for overcoming tumor resistance. A comprehensive narrative review was conducted focusing on recent advances in nano-phytomedicine, ferroptosis-based anticancer strategies and precision nanotherapeutic approaches. Relevant literature was systematically collected from PubMed, Scopus, ScienceDirect and Web of Science databases, considering both preclinical and clinical studies. Retrieved studies were critically analyzed to evaluate the therapeutic effects of nano-engineered phytochemicals on major oncogenic signaling pathways, including PI3K/Akt, NF-κB, STAT3, HIF-1α and NRF2. Mechanistic evidence associated with ferroptosis induction, reactive oxygen species (ROS) modulation, oxidative stress regulation, immune reprogramming and tumor microenvironment (TME) remodeling was systematically assessed. Preclinical studies indicate that nano-engineered phytochemicals can modulate interconnected oncogenic, metabolic, redox and immune pathways and can improve physicochemical and pharmacokinetic properties relative to free phytochemicals. Ferroptosis-associated effects include modulation of glutathione metabolism, GPX4, SLC7A11, iron homeostasis and lipid peroxidation; however, these molecular changes do not independently establish ferroptotic cell death. Evidence for tumour-microenvironment modulation and multidrug-resistance reversal remains predominantly preclinical, whereas human studies are limited and mainly address pharmacokinetic, tolerability or early efficacy outcomes. Nano-engineered phytochemicals represent a promising systems-oriented therapeutic strategy, but their clinical potential remains incompletely established. Future development requires rigorous mechanistic validation, reproducible formulation and manufacturing processes, biomarker-guided clinical evaluation, and comprehensive assessment of biodistribution, toxicity and long-term safety. Clinical trial: The manuscript is a review article (not a part of Clinical trial), hence no Clinical trial no is applicable.

  • Quantum-Engineered Polymeric Nanonetworks for Receptor-Targeted Drug Delivery: Molecular Determinants of Signaling Modulation and PK/PD Optimization

    by Kamlesh Sahu, Trilochan Satapathy, Poonam Sahu, Abhisek Satapathy

    Introduction/Objective: Quantum-Engineered Polymeric Nanonetworks (QEPNs) represent an emerging platform for targeted drug delivery that integrates polymer nanostructure engineering with quantum-scale electronic modulation. By exploiting phenomena such as quantum confinement and coherence-driven charge redistribution, QEPNs may regulate ligand-receptor interactions, enhance targeting precision, and improve therapeutic selectivity. This study aimed to describe the design principles and therapeutic potential of QEPNs for receptor-targeted drug delivery and signaling modulation. Methods: QEPNs were rationally designed through controlled modulation of polymer backbone conjugation, crosslink density, and network topology to optimize electronic coupling and multivalent receptor engagement. Quantum-informed Pharmacokinetic/Pharmacodynamic (PK/PD) modeling was employed to investigate cooperative binding mechanisms, receptor residence time, association kinetics, and nonlinear dose-response relationships associated with nanonetwork-mediated signaling modulation. Results: The engineered QEPNs demonstrated enhanced receptor-binding stability, prolonged receptor engagement, and improved selectivity toward tissues exhibiting receptor overexpression. These properties were associated with increased cellular uptake, sustained signaling activity, and controlled drug-release profiles, while reducing potential off-target interactions. Furthermore, quantum-informed PK/PD analysis indicated improved association kinetics and enhanced therapeutic efficiency at reduced drug concentrations, supporting the potential of QEPNs for precision drug delivery. Discussion: The findings suggest that integrating quantum-engineering principles with polymeric nanonetwork architecture may provide additional control over receptor recognition, cellular uptake, and drug-release behavior. The combination of multivalent receptor engagement and quantum-informed PK/PD modeling may enable more precise modulation of therapeutic exposure and signaling responses than conventional polymeric delivery systems. However, these proposed advantages require systematic experimental validation, particularly regarding the relationship between quantum-scale physicochemical properties, biological interactions, pharmacokinetics, and therapeutic outcomes. Conclusion: QEPNs provide a potentially transformative framework for precision drug delivery by integrating quantum engineering with polymer-based nanotherapeutic systems. Their ability to modulate receptor interactions, cellular uptake, and drug-release characteristics may improve therapeutic selectivity and efficiency. Further studies addressing long-term safety, biological validation, scalable manufacturing, reproducibility, and regulatory requirements are essential to determine their translational potential.

  • From Soybean Oil to Signaling Molecules: Oxylipins as Pharmacologically Active Lipids Modulating Liver and Metabolic Health

    by Kamlesh Sahu, Trilochan Satapathy, Poonam Sahu, Abhisek Satapathy, Om Chandrakar

    Introduction: Glucolipid metabolic disorders, including Metabolic Dysfunction- Associated Steatotic Liver Disease (MASLD), formerly known as Non-Alcoholic Fatty Liver Disease (NAFLD), insulin resistance, Type 2 Diabetes Mellitus (T2DM) and obesity, are characterized by dysregulated hepatic lipid metabolism, impaired glucose homeostasis and systemic energy imbalance. Oxylipins, a diverse class of oxygenated bioactive metabolites derived from Polyunsaturated Fatty Acids (PUFAs), have emerged as key lipid mediators that link dietary fatty acid composition to intracellular metabolic signaling pathways. Soybean oil, a major dietary source of linoleic acid and α-linolenic acid, provides abundant substrates for oxylipin biosynthesis via cyclooxygenase (COX), lipoxygenase (LOX), cytochrome P450 (CYP), and non-enzymatic oxidative pathways. This review comprehensively examines the mechanistic roles of soybean oil-derived oxylipins in regulating hepatic glucolipid metabolism and highlights their potential as therapeutic targets and diagnostic biomarkers for glucolipid metabolic disorders. Methods: Relevant peer-reviewed studies were identified through a comprehensive review of experimental, clinical, and lipidomics-based literature. Evidence related to oxylipin biosynthesis, receptormediated signaling, metabolic regulation, oxidative stress, inflammation, and glucolipid metabolic disorders was critically evaluated and systematically synthesized to provide an integrated mechanistic framework and highlight the therapeutic and diagnostic potential of oxylipins in metabolic diseases. Results: Current evidence indicates that oxylipins play pivotal roles in regulating glucolipid metabolism by activating G protein-coupled receptors and nuclear receptors, including Peroxisome Proliferator- Activated Receptor-α (PPARα), Peroxisome Proliferator-Activated Receptor-γ (PPARγ) and Liver X Receptors (LXRs). Through these signaling pathways, oxylipins regulate fatty acid oxidation, de novo lipogenesis, gluconeogenesis and insulin signaling, thereby maintaining metabolic homeostasis. Linoleic acid-derived oxylipins are generally associated with enhanced oxidative stress, mitochondrial dysfunction, chronic inflammation and insulin resistance. In contrast, cytochrome P450 (CYP)-derived epoxy-fatty acids exhibit anti-inflammatory, antioxidant and insulin-sensitizing properties that promote hepatic metabolic homeostasis. Moreover, disease-specific alterations in oxylipin profiles are strongly associated with hepatic lipid accumulation, lipid peroxidation and the progression of metabolic dysfunction, highlighting their potential as diagnostic biomarkers and therapeutic targets for glucolipid metabolic disorders. Discussion: The available evidence indicates that oxylipins exert both protective and detrimental effects, depending on their biosynthetic origin, fatty acid precursor and receptor specificity. Although considerable progress has been made in elucidating oxylipin-mediated metabolic signaling, variations in experimental models, analytical methodologies and clinical populations continue to limit the translation of these findings into therapeutic applications. Future studies integrating standardized lipidomic profiling with mechanistic investigations and well-designed clinical studies are essential to validate oxylipin-based biomarkers, establish causal relationships and facilitate the development of targeted therapeutic strategies for glucolipid metabolic disorders. Conclusion: Oxylipins are key regulators of hepatic glucolipid metabolism, linking dietary lipid metabolism with oxidative stress, inflammatory signaling and insulin sensitivity. Their diverse biological functions and context-dependent effects underscore their potential as diagnostic biomarkers and therapeutic targets for MASLD, insulin resistance, type 2 diabetes mellitus, obesity and other glucolipid metabolic disorders.

  • Open Access

    Stimuli-responsive quantum-engineered polymeric networks: From molecular design and scalable manufacturing to high performance cargo loading systems

    by Trilochan Satapathy, Om Chandrakar, Abhisek Satapathy, Poonam Sahu, Kamlesh Sahu, Gopendra Patel, Abinash Satapathy

  • Open Access

    RNAi-Loaded Nanocarriers Targeting the IL-6/JAK-STAT3-NF-κB Cytokine Axis in Rheumatoid Arthritis

    by Khemkaran Ahirwar, Shiv Kumar Bhardwaj, Abinash Satapathy, Abhisek Satapathy

    Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent synovial inflammation, progressive cartilage degradation, and bone erosion driven by complex cytokine-mediated signaling networks. Central to its pathogenesis is the dysregulated interplay of the interleukin-6 (IL-6)/Janus kinase (JAK)-signal transducer and activator of transcription-3 (STAT3) and nuclear factor kappa-B (NF-κB) pathways, which coordinate transcription of pro-inflammatory cytokines, angiogenic mediators, and osteoclastogenic factors. Conventional therapeutic strategies, including biologics and small-molecule inhibitors, primarily target extracellular mediators and often fail to adequately suppress intracellular signaling redundancy, leading to incomplete or transient clinical responses. RNA interference (RNAi) has emerged as a promising gene-silencing approach capable of selectively downregulating disease-driving transcripts at the post-transcriptional level. However, the clinical translation of RNAi is limited by instability, poor cellular uptake, and rapid degradation of naked small interfering RNA (siRNA). Nanocarrier-based delivery systems provide a transformative solution by protecting siRNA, enhancing pharmacokinetics, enabling targeted delivery to pathogenic cells, and facilitating cytoplasmic release through stimuli-responsive mechanisms. These RNAi-loaded nanoplatforms can simultaneously modulate multiple inflammatory nodes, reprogram immune-cell behavior, attenuate oxidative stress, and inhibit osteoclast genesis, thereby addressing RA as a systems-level disease. Furthermore, advances in precision targeting and multifunctional nanotechnology highlight the broader applicability of this strategy to other cytokine-driven disorders. Despite existing translational challenges, RNAi nanomedicine represents a paradigm shift toward network-oriented, gene-level therapeutics with the potential to achieve durable immunomodulation and disease modification in rheumatoid arthritis. Keywords: Inflammation; JAK-STAT3 signaling; nanocarriers; NF-κB; RNA interference; rheumatoid arthritis

  • Open Access

    Smart Nanocarrier Systems for Diabetic Wound Healing: Preclinical Innovations and Clinical Progress in Drug and Gene Delivery

    by Praveen Bhat, Abinash Satapathy, Neha Yadav, Abhisek Satapathy, Kunal Chandrakar, Ansuman Satapathy, Shiv Kumar Bhardwaj, Nikita Patel

    Diabetic wounds represent a complex clinical challenge arising from the convergence of chronic inflammation, impaired angiogenesis, oxidative stress, neuropathy, infection, and dysregulated extracellular matrix remodeling. Conventional therapies targeting single pathological components have shown limited efficacy, underscoring the need for integrated and mechanistically informed treatment strategies. This review comprehensively examines nanocarrier-mediated drug delivery systems as a transformative platform for diabetic wound management, integrating herbal, synthetic, semi-synthetic and gene-based therapeutics across preclinical and clinical landscapes. Emphasis is placed on the molecular pathophysiology of diabetic wounds and how advanced nanocarrier platforms enable spatiotemporal control, enhanced bioavailability, and pathway-specific modulation of inflammatory, angiogenic, antimicrobial, and regenerative processes. Material-driven functionalities, including stimuli-responsive release and multifunctional hybrid systems are critically discussed in relation to disorder-specific wound phenotypes. Furthermore, the review evaluates current preclinical models, translational barriers and emerging clinical trends, highlighting the importance of patient stratification and precision wound nanomedicine. Collectively, this work positions nanocarrier-based therapeutics as a promising and adaptable approach capable of addressing the biological heterogeneity of diabetic wounds and advancing toward clinically meaningful outcomes. Keywords: angiogenesis; diabetic wounds; gene therapy; herbal therapeutics; nanocarriers; wound healing


  • Open Access

    Intranasal nanoparticulate drug delivery systems for neurodegenerative disorders: an Overview

    by Poonam Sahu, Kunal Chandrakar, Princy Kashyap, Manoj Kumar, Arvind Kumar, Abhisek Satapathy, Abinash Satapathy, Shiv Kumar Bhardwaj, Trilochan Satapathy, Manisha Chandrakar

    Intranasal nanoparticulate drug delivery systems have received increased attention in pharmaceutical research due to their ability to increase drug bioavailability, bypass the blood-brain barrier (BBB), and provide non-invasive, patient-friendly alternatives to drug administration, particularly for drugs intended for central nervous system (CNS) disorders. Drugs delivered via nasal route can enter the CNS via the olfactory pathway or the trigeminal nerve pathway, enabling access to deeper regions. Intranasal nanoparticulate systems have several pharmacological benefits, including increased bioavailability, a faster onset of action, higher patient compliance, and less systemic adverse effects. Intranasal nanoparticulate drug delivery has shown promise in a variety of therapeutic areas, including Alzheimer's disease, Parkinson's disease, depression, and anxiety. Intranasal vaccinations and antibacterial Nanoparticle are also utilized to treat respiratory and viral illnesses. This technique is thought to be useful in brain-targeted chemotherapeutic drugs for glioblastoma treatment. The authors of this review attempted to investigate the pharmacological features of nanoparticulate drug delivery systems, including their benefits, mechanisms, formulation methodologies, and clinical applications. Keywords: Alzheimer's disease, Drug delivery, Nanoparticle, Nasal route, Neuro inflammation, Parkinson’s disease,